Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Pathogenesis and treatment of acute myeloid leukemia with FLT3 mutations].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Jan 2024

Ishikawa Yuichi

Abstract excerpt

FLT3 mutations are the most frequently identified genetic abnormalities in adult acute myeloid leukemia (AML) patients, accounting for approximately 30%. FLT3-ITD mutation specifically is considered as a poor prognostic factor in AML, and allogeneic hematopoietic cell transplantation in first remission is recommended for younger patients. The recent clinical introduction of FLT3 inhibitors has been reported to...

Topics

fms-Like Tyrosine Kinase 3
Humans
Leukemia, Myeloid, Acute
Mutation
Protein Kinase Inhibitors

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 39358294
DOI: 10.11406/rinketsu.65.945

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-39358294-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Pathogenesis and treatment of acute myeloid leukemia with FLT3 mutations].PMID 39358294Read ↗

[Current status and challenges of AML treatment with FLT3 inhibitors].Semantic proximity Read ↗

[Breakthroughs in FLT3-mutated acute myeloid leukemia treatments].Semantic proximity Read ↗

Advances in the pathogenesis of FLT3 -mutated acute myeloid leukemia and targeted treatments.Semantic proximity Read ↗

[Research Progress of FLT3 Mutation in Acute Myeloid Leukemia --Review].Semantic proximity Read ↗

FLT3 Mutations in Acute Myeloid Leukemia: Unraveling the Molecular Mechanisms and Implications for Targeted TherapiesSemantic proximity Read ↗

FLT3-targeted treatment for acute myeloid leukemia.Semantic proximity Read ↗

“FLipping” the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 InhibitorsSemantic proximity Read ↗

[FLT3 inhibitors in the treatment of FLT3-mutated acute myeloid leukemia].Semantic proximity Read ↗

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

[Mutations of the gene coding for the receptor tyrosine kinase FLT3 in acute myeloid leukemia. Significance as the disease-specific molecular marker for diagnosis, prognosis and innovative therapy approaches].Semantic proximity Read ↗

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemiaSemantic proximity Read ↗

FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging ControversiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.